COMBINATION OF MCL-1 INHIBITOR AND TAXANE COMPOUND, THEIR APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS Russian patent published in 2021 - IPC A61K31/337 A61K31/519 A61P35/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: first invention is a combination for the treatment of mammary gland cancer or lung cancer, containing: (a) MCL-1 inhibitor, which is (2R)-2-{[(5S_a)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(5-fluorofuran-2-yl)thieno[2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]methoxy}phenyl)propanoic acid or (2R)-2-{[(5S_a)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid, or their enantiomers, diastereoisomers, atropisomers or their addition salts with pharmaceutically acceptable acid or base, and (b) a taxane compound, which is paclitaxel or docetaxel, for simultaneous, sequential or separate use. The group of inventions also includes: the specified combination for the use for the treatment of mammary gland cancer or lung cancer; a pharmaceutical composition containing the specified combination with one or several pharmaceutically acceptable fillers; the use of the specified combination for the preparation of a drug for the treatment of mammary gland cancer or lung cancer; a drug separately or jointly containing the specified combination components; a method for the treatment of mammary gland cancer or lung cancer, including the injection of the specified combination; and a method for the sensitization of a patient, including the injection of the specified combination.

EFFECT: group of inventions provides for the synergetic action of the combination of MCL-1 inhibitor and taxane compound.

24 cl, 4 tbl, 9 ex